{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T19:58:43Z","timestamp":1794081523418,"version":"4.8.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.radonc.2024.110594","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T21:34:57Z","timestamp":1729719297000},"page":"110594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8871-4654","authenticated-orcid":false,"given":"Brigitta G.","family":"Baumert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"P. M. Jaspers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-3506","authenticated-orcid":false,"given":"Vera C.","family":"Keil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2485-1796","authenticated-orcid":false,"given":"Norbert","family":"Galldiks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-1326","authenticated-orcid":false,"given":"Ewa","family":"Izycka-Swieszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Timmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2255-2255","authenticated-orcid":false,"given":"Anca L.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-1603","authenticated-orcid":false,"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-7621","authenticated-orcid":false,"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Dhermain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien C.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Erridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.radonc.2024.110594_b0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2024.110594_b0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5858\/arpa.2021-0295-CP","article-title":"Molecular biomarker testing for the diagnosis of diffuse gliomas","volume":"146","author":"Brat","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.radonc.2024.110594_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2024.110594_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2016.09.018","article-title":"Consensus opinion on MRI simulation for external beam radiation treatment planning","volume":"121","author":"Paulson","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110594_b0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.radonc.2018.08.002","article-title":"High-resolution FLAIR MRI at 7 Tesla for treatment planning in glioblastoma patients","volume":"130","author":"Regnery","year":"2019","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.radonc.2024.110594_b0040","first-page":"1188","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials","volume":"17","author":"Ellingson","year":"2015","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.radonc.2024.110594_b0045","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3174\/ajnr.A6096","article-title":"Brain tumor-enhancement visualization and morphometric assessment: a comparison of MPRAGE, SPACE, and VIBE MRI techniques","volume":"40","author":"Danieli","year":"2019","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.radonc.2024.110594_b0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00066-020-01604-0","article-title":"Magnetic resonance imaging for brain stereotactic radiotherapy : a review of requirements and pitfalls","volume":"196","author":"Putz","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"10.1016\/j.radonc.2024.110594_b0055","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/cancers13051063","article-title":"Advanced imaging techniques for radiotherapy planning of gliomas","volume":"13","author":"Castellano","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0060","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3171\/2013.1.JNS121","article-title":"Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article","volume":"118","author":"Capelle","year":"2013","journal-title":"Journal of Neurosurgery JNS"},{"issue":"33","key":"10.1016\/j.radonc.2024.110594_b0065","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2024.110594_b0070","first-page":"719","article-title":"Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy","volume":"19","author":"van West","year":"2017","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2024.110594_b0075","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/neuonc\/noz042","article-title":"Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy","volume":"21","author":"Ludmir","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2024.110594_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109674","article-title":"Early and late contrast enhancing lesions after photon radiotherapy for IDH mutated grade 2 diffuse glioma","volume":"184","author":"Jaspers","year":"2023","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2024.110594_b0085","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00066-016-1005-9","article-title":"Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma","volume":"192","author":"Harrabi","year":"2016","journal-title":"Strahlenther Onkol"},{"issue":"1076","key":"10.1016\/j.radonc.2024.110594_b0090","doi-asserted-by":"crossref","first-page":"20160406","DOI":"10.1259\/bjr.20160406","article-title":"Can CT scan protocols used for radiotherapy treatment planning be adjusted to optimize image quality and patient dose? a systematic review","volume":"90","author":"Davis","year":"2017","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/neuonc\/nos300","article-title":"[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma","volume":"15","author":"Hutterer","year":"2013","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.radonc.2024.110594_b0100","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00259-010-1457-6","article-title":"Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance?","volume":"37","author":"Pichler","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0105","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00259-012-2109-9","article-title":"MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?","volume":"39","author":"Jansen","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.radonc.2024.110594_b0110","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/neuonc\/noac040","article-title":"Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas","volume":"24","author":"Ninatti","year":"2022","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.radonc.2024.110594_b0115","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/neuonc\/noz083","article-title":"Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients","volume":"21","author":"Galldiks","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0120","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1097\/RLU.0000000000003240","article-title":"Photopenic defects in gliomas with amino-acid PET and relative prognostic value: a multicentric 11C-methionine and 18F-FDOPA PET experience","volume":"46","author":"Zaragori","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"21","key":"10.1016\/j.radonc.2024.110594_b0125","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1158\/1078-0432.CCR-04-0262","article-title":"Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology","volume":"10","author":"Kracht","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"Pt 3","key":"10.1016\/j.radonc.2024.110594_b0130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awh399","article-title":"O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas","volume":"128","author":"Pauleit","year":"2005","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.radonc.2024.110594_b0135","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/neuonc\/not002","article-title":"Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study","volume":"15","author":"Pafundi","year":"2013","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0140","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00259-018-4107-z","article-title":"Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity","volume":"46","author":"Roodakker","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0145","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/neuonc\/noz180","article-title":"Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study","volume":"22","author":"Verburg","year":"2020","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0150","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s00259-019-04677-x","article-title":"Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas","volume":"47","author":"Sch\u00f6n","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0155","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/neuonc\/noab013","article-title":"Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET\/RANO group","volume":"23","author":"Galldiks","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0160","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0","volume":"46","author":"Law","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2024.110594_b0165","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2019.04.009","article-title":"The landscape of postsurgical recurrence patterns in diffuse low-grade gliomas","volume":"138","author":"Ferracci","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-019-03250-8","article-title":"Tumor recurrence patterns after surgical resection of intracranial low-grade gliomas","volume":"144","author":"Fukuya","year":"2019","journal-title":"J Neurooncol"},{"issue":"2","key":"10.1016\/j.radonc.2024.110594_b0175","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-020-03391-1","article-title":"Spatial distribution of malignant transformation in patients with low-grade glioma","volume":"146","author":"Jakola","year":"2020","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0180","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0360-3016(94)00400-F","article-title":"Low grade gliomas: preliminary analysis of failure patterns among patients treated using 3D conformal external beam irradiation","volume":"31","author":"Pu","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00000421-199802000-00005","article-title":"Patterns of tumor progression after radiotherapy for low-grade gliomas: analysis from the computed tomography\/magnetic resonance imaging era","volume":"21","author":"Rudoler","year":"1998","journal-title":"Am J Clin Oncol"},{"issue":"9490","key":"10.1016\/j.radonc.2024.110594_b0190","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial","volume":"366","author":"van den Bent","year":"2005","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.radonc.2024.110594_b0195","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2002.09.126","article-title":"Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group\/Radiation Therapy Oncology Group\/Eastern Cooperative Oncology Group study","volume":"20","author":"Shaw","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2024.110594_b0200","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1016\/j.prro.2019.02.002","article-title":"Patterns of failure among patients with low-grade glioma treated with proton radiation therapy","volume":"9","author":"Kamran","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110594_b0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.radonc.2020.11.019","article-title":"Pattern of failure in IDH mutated, low grade glioma after radiotherapy - Implications for margin reduction","volume":"156","author":"Jaspers","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00066-019-01467-0","article-title":"Pattern of failure in anaplastic glioma patients with an IDH1\/2 mutation Rezidivmuster bei Patienten mit anaplastischem Glioma mit einer IDH1\/2-Mutation","volume":"196","author":"Back","year":"2020","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0215","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41598-017-19014-1","article-title":"Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification","volume":"8","author":"Im","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0220","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0360-3016(96)00352-5","article-title":"A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844","volume":"36","author":"Karim","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"25","key":"10.1016\/j.radonc.2024.110594_b0225","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2011.35.8598","article-title":"Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802","volume":"30","author":"Shaw","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0230","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijrobp.2014.11.012","article-title":"Phase 2 Study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424","volume":"91","author":"Fisher","year":"2015","journal-title":"Int J Radiat Oncol *Biol *Phys"},{"issue":"11","key":"10.1016\/j.radonc.2024.110594_b0235","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033\u201326033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110594_b0240","doi-asserted-by":"crossref","unstructured":"Intergroup Radiation Therapy Oncology Group Trial 9402., et al., Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol, 2006. 24(18): p. 2707-14.","DOI":"10.1200\/JCO.2005.04.3414"},{"issue":"18","key":"10.1016\/j.radonc.2024.110594_b0245","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.2005.04.6078","volume":"24","author":"van den Bent","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10103","key":"10.1016\/j.radonc.2024.110594_b0250","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","article-title":"Interim results from the CATNON trial (EORTC study 26053\u201322054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study","volume":"390","author":"van den Bent","year":"2017","journal-title":"Lancet"},{"issue":"35","key":"10.1016\/j.radonc.2024.110594_b0255","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","article-title":"NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide","volume":"27","author":"Wick","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0260","doi-asserted-by":"crossref","first-page":"e0150326","DOI":"10.1371\/journal.pone.0150326","article-title":"Quantification and assessment of interfraction setup errors based on cone beam CT and determination of safety margins for radiotherapy","volume":"11","author":"Cubillos Mes\u00edas","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2024.110594_b0265","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.radonc.2021.05.013","article-title":"Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology","volume":"160","author":"Eekers","year":"2021","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2017.12.013","article-title":"The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology","volume":"128","author":"Eekers","year":"2018","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0275","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2015.07.041","article-title":"CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines","volume":"117","author":"Brouwer","year":"2015","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0280","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2018.05.001","article-title":"Radiation dose constraints for organs at risk in neuro-oncology; the European particle therapy network consensus","volume":"128","author":"Lambrecht","year":"2018","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0285","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2013.05.007","article-title":"Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach","volume":"107","author":"Langendijk","year":"2013","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0290","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.clon.2021.12.015","article-title":"Normal tissue complication probability modelling for toxicity prediction and patient selection in proton beam therapy to the central nervous system: a literature review","volume":"34","author":"Gaito","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"34","key":"10.1016\/j.radonc.2024.110594_b0295","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","article-title":"Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial","volume":"32","author":"Gondi","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0300","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-018-03063-1","article-title":"Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide","volume":"142","author":"Dworkin","year":"2019","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0305","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11060-022-04217-y","article-title":"Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3","volume":"162","author":"Eichkorn","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2024.110594_b0310","article-title":"Pseudoprogression is frequent following front-line radiotherapy in pediatric low-grade glioma - results from the German LGG cohort","author":"Stock","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.radonc.2024.110594_b0315","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/0284186X.2023.2200150","article-title":"Transitioning from conventional photon therapy to proton therapy for primary brain tumors","volume":"62","author":"Ek","year":"2023","journal-title":"Acta Oncol"},{"issue":"21","key":"10.1016\/j.radonc.2024.110594_b0320","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215287","article-title":"Oncological outcomes, long-term toxicities, quality of life and sexual health after pencil-beam scanning proton therapy in patients with low-grade glioma","volume":"15","author":"Willmann","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3-5","key":"10.1016\/j.radonc.2024.110594_b0325","first-page":"198","article-title":"Stereotactic treatment of brain lesions. Biopsy, interstitial radiotherapy (iridium-192 and iodine-125) and drainage procedures","volume":"43","author":"Mundinger","year":"1980","journal-title":"Appl Neurophysiol"},{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0330","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1227\/00006123-198112000-00022","article-title":"Interstitial irradiation of brain tumors: a review","volume":"9","author":"Bernstein","year":"1981","journal-title":"Neurosurgery"},{"key":"10.1016\/j.radonc.2024.110594_b0335","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1748-717X-7-30","article-title":"Iodine-125 brachytherapy for brain tumours\u2013a review","volume":"7","author":"Schwarz","year":"2012","journal-title":"Radiat Oncol"},{"issue":"31","key":"10.1016\/j.radonc.2024.110594_b0340","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2011.37.3381","article-title":"Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome","volume":"29","author":"Ruge","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.radonc.2024.110594_b0345","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/neuonc\/nor100","article-title":"Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection","volume":"13","author":"Suchorska","year":"2011","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.radonc.2024.110594_b0350","first-page":"e9666","article-title":"Re-irradiation using brachytherapy for recurrent intracranial tumors: a systematic review and meta-analysis of the literature","volume":"12","author":"Choi","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.radonc.2024.110594_b0355","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13014-020-01719-9","article-title":"Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas","volume":"15","author":"Watson","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110594_b0360","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-7-94","article-title":"Stereotactic iodine-125 brachytherapy for brain tumors: temporary versus permanent implantation","volume":"7","author":"Ruge","year":"2012","journal-title":"Radiat Oncol"},{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0365","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/neuonc\/noaa021","article-title":"Final report from Intergroup NCCTG 86\u201372-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma","volume":"22","author":"Breen","year":"2020","journal-title":"Neuro Oncol"},{"issue":"14","key":"10.1016\/j.radonc.2024.110594_b0370","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.radonc.2024.110594_b0375","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053\u201322054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0380","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0385","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2024.110594_b0390","first-page":"1529","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2024.110594_b0395","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2967\/jnumed.123.266205","article-title":"Theranostics in neurooncology: heading toward new horizons","volume":"65","author":"Tolboom","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2024.110594_b0400","first-page":"noae078","article-title":"PET imaging of gliomas: Status quo and quo vadis?","volume":"6","author":"Galldiks","year":"2024","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0405","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1078-0432.CCR-20-0894","article-title":"Hypofractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice","volume":"27","author":"Montay-Gruel","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.radonc.2024.110594_b0410","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.radonc.2024.110594_b0415","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2003.06.023","article-title":"Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities","volume":"21","author":"Buckner","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2024.110594_b0420","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ijrobp.2020.03.027","article-title":"Phase 2 study of a temozolomide-based chemoradiation therapy regimen for high-risk, low-grade gliomas: long-term results of radiation therapy oncology group 0424","volume":"107","author":"Fisher","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.radonc.2024.110594_b0425","first-page":"252","article-title":"Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813","volume":"19","author":"Chang","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2024.110594_b0430","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/neuonc\/noaa168","article-title":"CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p\/19q codeleted oligodendroglioma. Analysis from the initial study design","volume":"23","author":"Jaeckle","year":"2021","journal-title":"Neuro Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024035722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024035722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:29:56Z","timestamp":1734568196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024035722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":86,"alternative-id":["S0167814024035722"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110594","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110594"}}